Close

BTIG Upgrades Neogenomics (NEO) to Buy

Go back to BTIG Upgrades Neogenomics (NEO) to Buy

NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

October 26, 2016 8:42 AM EDT

NeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.8 million versus the consensus estimate of $61 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.14-$0.16, versus prior guidance of $0.08-$0.13 and the... More